- $12.51m
- -$43.35m
- 28
- 55
- 27
- 29
Annual cashflow statement for NextCure, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -36.6 | -69.4 | -74.7 | -62.7 | -55.7 |
| Depreciation | |||||
| Non-Cash Items | 7.91 | 13.3 | 13 | 8.01 | 7.45 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -19.7 | -5.38 | 3.73 | -1.94 | 4.53 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -45 | -57.3 | -53.9 | -53 | -40.8 |
| Capital Expenditures | -7.13 | -2.36 | -2.12 | -0.82 | -0.474 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 50.7 | 39 | 70.1 | 40.1 | 55.8 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 43.5 | 36.6 | 68 | 39.3 | 55.3 |
| Financing Cash Flow Items | — | — | — | — | 0.039 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1.42 | -3.27 | 0.2 | 0.154 | 0.144 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.85 | -23.9 | 14.3 | -13.5 | 14.6 |